After San Francisco,Tokyo and Boston, the Meet the Experts Transporter meeting is returning to Budapest in the spring of 2016. The Meet the Experts Transporter meeting is focused on bringing you the latest developments in the field of transporters, covering a wide range of topics. Previous meetings included symposia such as Methods and Models, The Physiological Function of Transporters, The Role of Transporters in Disease, Transporters in Drug Discovery and Development and Transporter – Enzyme Interplays. Each symposium consists of presentations by speakers from industry and academia, combining fundamental research with practical insights, followed by an interactive Q&A session.
The meeting’s main conclusions, presented novelties and future directions are summarized by Peter Krajcsi, SOLVO’s CSO. The Meet the Experts Transporter conferences are relatively small meetings with 70-100 participants, and offer plenty of opportunities for networking with colleagues in the field or personal interaction with the speakers. Being held in Budapest, the 2016 spring meeting also provides a unique opportunity for you to meet SOLVO’s scientists, project managers and study directors.
Last but not least, Budapest is one of the highest rated cities to visit in Europe. This is your chance to combine work and fun, visiting the famous coffee houses, spas and museums before diving into the world of Transporters! Conference sponsor:
The following speakers are presenting at the conference.
Principal Scientist Discovery DMPK Lundbeck AS, Copenhagen, Denmark
Dr. Lassina Badolo is graduated Pharmacist from Free University of Brussels and took his PhD from the same university. Lassina has both an industry and academia background spending more than 13 years in the industry and 2.5 years as associate professor at the University of Copenhagen. The focus of his research has been on investigating hepatic drug transporter in isolated hepatocytes, assessing the change in function and expression in different culture conditions. Lassina has published more than 25 papers and presented his research as invited speaker in more than a dozen conferences. He has directed a number of master and PhD projects during the last decade. Lassina is currently employed in Discovery DMPK at Lundbeck AS as principal scientist.
Lecturer in Drug Delivery School of Pharmacy University of Nottingham Nottingham, United Kingdom
Dr.Cynthia Bosquillon is Lecturer in Drug Delivery at the University of Nottingham, School of Pharmacy, UK. She obtained her Master of Pharmacy and PhD from the Université catholique de Louvain, Belgium. Following her PhD, she worked as a post-doctoral researcher at King’s College London on a project directed by Prof.Ben Forbes before being awarded a 2 year fellowship that she undertook at the same institution and finally, being appointed to a lectureship at Nottingham. Her research has essentially focussed on drug inhalation, of which she has explored different aspects, from the formulation and characterisation of dry powders to the development of in vitro and ex vivo models of the lungs as tools to predict pulmonary drug absorption in vivo. She has published two book chapters and more than 20 papers in the field, including the first review on drug transporters in the lungs. She has collaborated with the pharmaceutical industry on various lung projects and has been invited to talk at several national and international meetings.
Associate Professor Institute for Cell & Molecular Biosciences, Medical School, Newcastle University Newcastle, UK
Dr Colin Brown was awarded a B.Sc and Ph.D in Physiology and Pharmacology from the University of St Andrews Scotland. He then was a Royal Society European Postdoctoral Research Fellow at the University of Zurich, Switzerland, followed by a Wellcome Trust Senior Fellowship in Biomedical Sciences at the University of Manchester. Until recently, Colin was an Associate Professor at the University of Newcastle where he focussed on developing in vitro models to study drug transport, drug interactions and toxicity in kidney, developing the aProximate in vitro PTC model. In 2018, Dr Brown joined Newcells Biotech as Director of ADMET Technologies.
MD, DTM&H Unit of Infectious Diseases, Department of Medical Sciences, University of Torino Torino, Italy
Dr Calcagno is temporary Assistant Professor at the University of Torino (Department of Medical Sciences, Infectious Diseases). Infectious Diseases Specialist (University of Torino, Italy); Diploma in Tropical Medicine and Hygiene (Mahidol University, Bangkok, Thailand). He is member of the Panel of the Italian Guidelines on the Use of Antiretrovirals and Management of patients living with HIV. He has experience as a Clinicians in Infectious Diseases and Tropical Medicine (Sudan, Thailand, Burundi); several phase II, III and IV studies in antiretroviral treatment trials. His main field of interest is the clinical pharmacology and pharmacogenetics of anti-infective agents (antiretroviral, antibiotic, antifungals) and the central nervous system complication of HIV-infection.
Head of Division of Pharmacology Leiden Academic center for Drug Research (LACDR), Leiden University, The Netherlands
Elizabeth de Lange, PhD, is Head of Division of Pharmacology at the Leiden Academic center for Drug Research (LACDR), Leiden University, the Netherlands. Her ultimate aim is to aid in the prediction of the dose-response relationship of CNS drugs in the clinical setting on the basis of preclinical data (translational research) by identification and characterization of the rate and extent of systems processes that govern the dose-response relationship of CNS drugs in health and CNS disorders. This includes not only BBB transport but also intra-brain distribution of drugs and associated CNS effects. To that end, Elizabeth de Lange’s group combines comprehensive preclinical experimentation (intracerebral microdialysis, EEG monitoring, PET scanning, etc) with advanced mathematical modeling. She provides general pharmacokinetic and BBB lecture series for Bio-Pharmaceutical Sciences Students. Furthermore, Dr de Lange has been the cofounder and (co-)Chair at the 1st, 2nd and 5th of the series of International Symposia on Microdialysis in Drug Research and Development. She has been the Chair of the Organizing Committee of the 9th International CerebroVascular Biology Conference, held in Leiden, The Netherlands, in 2011. Furthermore, she has been the chair of the Microdialysis Focus Group (2005-2007), of the Pharmacokinetics Pharmacodynamics and drug metabolism (PPDM)(2012)section, and OF the Annual Meeting Programming Committee (AMPC) (2014) of the American Association of Pharmaceutical Scientists (AAPS), With her company In Focus (www.infocus-ecmdelange.nl) she provides courses, training and advice within her area of expertise on microdialysis, PK, PKPD, BBB, and intra-brain distribution.
Head of Services SOLVO Biotechnology, Szeged, Hungary
Krisztina Herédi-Szabó, PharmD, PhD, has a degree in Pharmacy from the University of Szeged, Hungary. She has earned her PhD in the field of peptide chemistry and cell biology at Creighton University, Omaha, Nebraska, USA in 2005. She has joined Solvo Biotechnology in 2006 and started working in the field of transporter proteins. She was involved in the development of several transporter assays that are now available as products and services. She is an author of 21 scientific publications and presented her group’s work at several international conferences. Her current position is Head of Service laboratory at Solvo Biotechnology, Szeged, Hungary.
Department of Rheumatology Amsterdam Rheumatology and Immunology Center (ARC) Amsterdam, The Netherlands
Dr. Gerrit Jansen obtained his PhD degree in Biochemstry at the State University of Utrecht, The Netherlands in 1984. From 1985-1990 he held a post-doctoral position at the Utrecht University Medical Center (Dept. of Oncology). In 1991 he moved to the VU University Medical Center in Amsterdam (Dept. of Medical Oncology). From 1992-1994 he was a recipients of a fellowship of the Royal Netherlands Academy of Arts and Sciences, which was followed by a senior postdoctoral position at the VU University Medical Center (Dept. of Medical Oncology). In 2001 he moved to the Department of Rheumatology (currently Amsterdam Rheumatology and immunology Center) at the VU University Medical Center to become head of the laboratory for experimental rheumatology. Dr. Jansen’s main research interest focuses on molecular mechanisms of drug resistance, with a special interest for resistance mechanisms to classical (e.g. antifolates) and experimental drugs from an anti-inflammatory and anti-cancer perspective.
Drug Safety Consultant Macclesfield, Cheshire, United Kingdom
Dr. Gerry Kenna is a Drug Safety Consultant based in Cheshire, UK. He has extensive experience of safety assessment of pharmaceuticals and other chemicals and of toxicity testing and of mechanisms that underlie human adverse drug reactions, most notably liver toxicity. This was acquired while working as Scientific Director of FRAME (the Fund for the Replacement of Animals in Medical Experiments; www.frame.org.uk); in industry for AstraZeneca, Syngenta and Zeneca; and in academia at Imperial College School of Medicine, London UK; National Institutes of Health, MD USA; King’s College Hospital Medical School, London UK and the National Institute for Medical Research, London UK. Dr. Kenna continues to be actively involved in research on the mechanisms which underlie human adverse drug reactions and on the development and implementation of novel predictive safety screening strategies that take account of hepatobiliary transporter inhibition, metabolic bioactivation and immune responsiveness, plus PBPK-based in vitro/in vivo exposure scaling. He is also committed to implementation of improved human safety testing strategies that reduce, refine and replace a need for procedures on animals. Dr Kenna received a BSc in Biochemistry from the University of Leeds UK and a PhD in Biochemistry from the University of London UK. He has authored or co-authored >100 scientific publications and is a member of the International Society for the Study of Xenobiotics, and a Fellow of the British Toxicology Society.
Study Manager Services SOLVO Biotechnology Budaörs, Hungary
Anna Klukovits has over 16 years’ experience working in the field of experimental pharmacology. She received her Ph.D. in Clinical Medicine while studying the neural regulation of uterine functions during pregnancy in the rat. Started to work as Assistant Professor at the Department of Pharmacodynamics and Biopharmacy, at University of Szeged, Hungary and focused on finding potential new targets to treat premature birth. She spent 12 months as a visiting professor at Miller School of Medicine, University of Miami (FL) while conducting cell-based studies as well as in vivo animal studies in experimental oncology, in the research group of Nobel-laureate Andrew V. Schally. Anna joined SOLVO Biotechnology as Study Manager in 2012, now working as member of the European Market Group, where she is responsible for providing scientific consultation and coordinating contract research services with European Customers. She is the author of 20 research papers including reviews and of numerous presentations.
Chief Scientific Officer, SOLVO Biotechnology Budaors, Hungary
Dr. Peter Krajcsi has extensive experience in biotechnology. He received his PhD in biochemistry from University of Szeged and later a Doctor of Sciences degree in biological sciences from the Hungarian Academy of Sciences. In his academic career he has focused on three major topics (i) steroid receptors (ii) molecular biology of adenoviruses and (iii) apoptosis. For the past 13 years he has been working in R&D management positions for small and medium size enterprises in drug research and gene therapy in Hungary as well as in the United States. Since 2002 he is the Chief Scientific Officer of Solvo Biotechnology. At Solvo the focus is on membrane transporters and utilization of membrane transporter technology in drug discovery and development as well as in development of diagnostics tools for cancer and inflammatory diseases.
Adjunct Professor; ETH Zurich; Zurich, Switzerland
Stefanie D. Krämer is Adjunct Professor for Biopharmacy at the ETH Zurich (Switzerland). She studied Pharmaceutical Sciences at the ETH Zurich and after some practice as a pharmacist in a public pharmacy got her Ph.D. in natural sciences at the ETH. She strengthened her expertise in physico-chemical compound characterization and blood-brain barrier models during post-doctoral stays at Sanofi Recherche in Montpellier (F) and King’s College in London (UK). Back at the ETH, she habilitated in 2007 in Biopharmacy (Drug Interactions with Lipid Bilayers and P glycoprotein) and is since 2009 involved in Radiopharmacology/Preclinical PET of Radiopharmaceutical Sciences at the ETH. Main research interests of Stefanie Krämer are kinetics of drug-lipid bilayer and transporter-mediated permeation, characterization of ADME (Absorption, Distribution, Metabolism, Excretion) properties of drugs and PET tracers, preclinical PET, in particular PET kinetic modeling and imaging of inflammatory processes. She teaches Biopharmacy/Pharmacokinetics (lecture and practical) and Biotransformation of Drugs and Xenobiotics (lecture) at the ETH. She co-authored the two-volume text book The Biochemistry of Drug Metabolism (Wiley) and has published more than 80 research papers. She wrote the Java applications PharmaCalc v02 and PharmaCalcCL to simulate plasma-concentration time curves (available on www.biopharmacy.ethz.ch).
Institute for Infection and Immunity St. George's, University of London London, United Kingdom
Sanjeev Krishna has developed new diagnostic approaches for infections and increased understanding of their pathophysiology as well as improving treatment modalities. His research has focused on infectious disease, particularly malaria, with a special interest in transporter proteins – the targets of existing antimalarial drugs as well as potential new drug targets. His wide-ranging research has spanned clinical trials of antimalarial treatments, mechanisms of drug resistance, and identification of the likely target of the current first-line antimalarial treatment, artemisinin. He has also identified transporter proteins as valid targets for new drug development. His research has fed into international guidelines on malaria treatment and global surveys of antimalarial resistance. He also has a strong interest in diagnostics, and, in developing an affordable point-of-care diagnostic device for drug resistance as well as identifying infections. More recently he is studying how to repurpose artemisinins (the discovery of which one this years Nobel Prize in Medicine) as cheap, safe, effective and affordable treatments for cancers.
Vice President of Operations Ascendance Biotechnology, Inc. Medford, MA, USA
Mr. McGeehan joined Ascendance Biotechnology, Inc. (“Ascendance”) (formerly Hepregen Corporation (“Hepregen”)) in March, 2009. During Hepregen‘s start-up phase, Mr. McGeehan was responsible for successfully scaling-up the company’s micropatterned co-culture technology, which was exclusively licensed from the Massachusetts Institute of Technology (“MIT”). In addition to being responsible for all operations and scientific groups at Ascendance, Mr. McGeehan is currently engaged in driving the commercialization of the Hepregen® line of application-directed assay kits and associated services worldwide. Mr. McGeehan has more than 25 years of technical and management experience in the biotechnology industry. He was a co-founder of ActiMed Laboratories, Inc. (“ActiMed”), a medical device company. As vice president of operations at ActiMed, Mr. McGeehan guided the development, scale-up, manufacture, and clinical trials, of the ENA•C•T® Total Cholesterol test. Prior to ActiMed, Mr. McGeehan was employed in positions of increasing responsibility at a division of E. Merck. At E. Merck, he managed the construction and start-up of a $1 million dry powder manufacturing facility. He leveraged the company’s fluid bed granulation technology into five distinct diagnostic reagent product lines, taking over 100 products to successful market introductions. Mr. McGeehan was also a founder of Innova Medical Technologies, Inc., providing general consulting and product development services to medical products companies. Mr. McGeehan holds a B.A. in biology from Millersville University and a M.S. in biomedical engineering from Drexel University. He is named as an inventor on seven US patents, including a key patent that provides tools essential to the routine, reproducible and economic manufacturing of the Hepregen line of high quality HepatoPac® and HepatoMune® products.
Metabolism Manager Department of Drug Metabolism and Pharmacokinetics Galderma R&D Sophia-Antipolis, France
Hanan Osman-Ponchet is currently a Metabolism Manager in the Department of Drug Metabolism and Pharmacokinetics at Galderma R&D in Sophia-Antipolis (France). Hanan has an MSc in Toxicology and Pharmacology and a PhD in Biochemistry, Cellular and Molecular Biology obtained at the University of Burgundy in France. Dr. Osman-Ponchet has worked in drug development for over 15 years. She first joined the pharmaceutical industry in 2002, initially at Sanofi, Paris area, where she was a Manager of in vitro Drug Metabolism and Absorption. She joined Galderma R&D in 2007, and led the development of in vitro technologies to predict drug metabolism, drug absorption and drug-drug interactions in both hepatocytes and skin. Hanan has more than 15 years of experience in in vitro DMPK and has expertise in drug transporters (intestinal and cutaneous absorption), drug metabolism (liver and skin) and drug-drug interactions. Hanan’s research interests include in vitro methodologies for prediction of drug-drug interactions at metabolism and transporter levels and imaging techniques for assessment of drug distribution in the skin. Hanan has authored and coauthored more than 30 research publications and patents, and has given invited oral presentations at several different scientific conferences. Dr. Osman-Ponchet is an expert in the area of drug metabolism and drug transporters in human skin.
Principal Scientist Drug Metabolism and Pharmacokinetics Genentech San Francisco, CA, USA
Dr. Laurent Salphati is currently a Principal Scientist in the Drug Metabolism and Pharmacokinetics department at
Genentech, Inc. He heads the Permeability/Drug Transporters group and has been supporting and leading immunology
and oncology project teams from preclinical discovery to late stage clinical development. He received his Pharm.D.
from the University of Paris XI, France, and conducted his Ph.D research, investigating the complementary roles of
P-glycoprotein and CYP3A in drug absorption and disposition, at the University of California, San Francisco under
the guidance of Dr. Leslie Z. Benet. His research interests include the pharmacokinetics and pharmacodynamics of
drugs (PK/PD and PB/PK modeling) and the roles of drug transporters in drug absorption and disposition.
Head of Research Group, Research Centre for Natural Sciences, Budapest, Hungary
Balázs Sarkadi, MD, Ph.D., spent several years as a post-doc and then as a visiting scientist at major universities in the United States and Canada. He is research professor at Semmelweis University, member of the Hungarian Academy of Sciences, past president of FEBS, member of several international research societies including the Academia Europeae. His research has been focusing on membrane proteins, including the investigation of ABC membrane transporters, which play a major role in the multidrug resistance of cancer, in general pharmacology, and in stem cell function. His recent work is related to transporter regulation in cancer cells and stem cells. He has published more than 300 papers in international scientific journals, with a citation number over 13,400 (in WoS, or 18,500 in Google Scholar) and an h-index of 61 (GS 69). He has several international patents already in commercial applications.
Senior Fellow and Director, DMPK, GlaxoSmithKline, Collegeville, PA, USA
Maciej Zamek-Gliszczynski has 15 years of industry (Eli Lilly and GSK) experience in leading DMPK and PK/PD/clinical pharmacology aspects of oncology, endocrine/metabolic, and infectious disease programs at all stages between discovery, clinical development, and post-marketing (6 clinical candidate selections & INDs, 2 NDAs). He is an experienced global manager, having led the Quantitative Drug Disposition group responsible for understanding victim and perpetrator DDIs for the entire GSK portfolio. Dr. Zamek-Gliszczynski’s research is focused on PK/PD and DDI implications of drug and metabolite transport. He is the author of >100 manuscripts and presentations on this subject (>5,000 cites, h-index = 35). He serves on the editorial boards of Pharmaceutical Research and Drug Metabolism and Disposition. Dr. Zamek-Gliszczynski is a member of the International Transport Consortium (ITC) steering committee, was past chair of AAPS PK/PD/Drug Metabolism (PPDM) section, and he served as GSK management representative on IQ Translational ADME Leadership Group (TALG). He has been active in organizing DMPK/clinical pharmacology meetings with ITC, ASCPT and AAPS. Dr. Zamek-Gliszczynski lectures in graduate-level PK/PD courses and serves as external committee advisor (including as adjunct prof at UNC). He enjoys developing scientists and has an established mentorship record at the associate scientist, junior and peer Ph.D., as well as graduate student and post-doc levels.
|Péter Krajcsi, SOLVO: Introduction|
|Keynote: Maciej Zamek-Gliszczynski, GSK: Transporters in Drug Development – Emerging Themes from the ITC|
|New Tools for old barriers|
|Bosquillon Cynthia, University of Notthingham: Tools to study pulmonary drug permeability|
|Jack McGeehan, Ascendance: A Review of HepatoPac® Products and Technology for DMPK and Toxicology Applications|
|Colin Brown, Newcastle University: A Proximate proximal tubule cells as predictive in vitro models of nephrotoxicity|
|Hanan Osman-Ponchet, Galderma: Characterization of drug transporters in human skin|
|Sára Karbanová, Charles University: Transport of ribavirin accross the rat and human placental barrier; role of nucleoside transporters|
|Keynote: Mohammed Ullah, Roche: Refinement of in vitro tools and IVIVE|
|Tools for translational transporter science|
|Elizabeth CM de Lange, Leiden University: The Impact of BBB and BCSFB Transporters in translational CNS drug distribution models|
|Lassina Badolo, Lundbeck: Regulation of hepatic transporters in isolated hepatocytes: Issues and opportunities|
|Laurent Salphati, Genentech: Humanized Animal Models - Potential Tools for the Study of Drug Transporters?|
|Paul Hagen, University Medicine Greifswald: Use of Förster resonance energy transfer (FRET) for functional characterization of OATP2B1|
|Abdullah Mayati, IRSET: Protein kinase c-dependent regulation of human hepatic drug transporter expression|
|Keynote: Balazs Sarkadi, Hungarian Academy of Sciences: The concept of chemoimmunity in ADME-Tox studies - ABC transporters in stem cells|
|Transporters as Biomakers, mediators of resistance and toxicity|
|Andrea Calcagno, University of Torino: Transporters and response to drugs: beyond plasma pharmacokinetics|
|Gerrit Jansen, VU University: Pharmacologic and physiologic role of ABC drug efflux transporters in auto-immune disease|
|Gerry Kenna, PhD, Drug Safety Consultant: BSEP inhibition and drug induced liver injury|
|Peter Szeremy, MDQuest Kft: Multidrug resistance (MDR) protein activity of T lymphocytes assessed by flow cytometry is a predictor of biological treatment response in rheumatoid arthritis|
|Peter Krajcsi: Bile salt transport profiling of hepatic uptake transporters|
|Transporters as therapeutic targets|
|Sanjeev Krishna, University London: Strategies exploiting transporters to overcome drug resistance in malaria|
|Stephan Urban, University Heidelberg: The Role of NTCP in the hepatic uptake of Hepatitis B and D viruses: Specific Inhibition of NTCP as a novel therapeutic option to treat infections|
|Stefanie Kramer, ETH Zurich: Imaging Uptake Transporter Activity in Cancer by Positron Emission Tomography (PET)|
|Selvi Durmus Erim, Bilkent University: Preclinical assessment of a novel palladium-based anticancer drug candidate: Assessing its pharmacokinetics and interaction with drug transporters|
|Péter Krajcsi, SOLVO: Closing Remarks for the Conference|